You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Investigational Drug Information for CC-220


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug CC-220?

CC-220 is an investigational drug.

There have been 28 clinical trials for CC-220. The most recent clinical trial was a Phase 2 trial, which was initiated on June 15th 2023.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Lymphoma. The leading clinical trial sponsors are Celgene, Celgene Corporation, and Bristol-Myers Squibb.

There are twenty-nine US patents protecting this investigational drug and two hundred and eighty international patents.

Recent Clinical Trials for CC-220
TitleSponsorPhase
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple MyelomaNational Cancer Institute (NCI)Phase 2
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyPhase 1
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaBristol-Myers SquibbPhase 3

See all CC-220 clinical trials

Clinical Trial Summary for CC-220

Top disease conditions for CC-220
Top clinical trial sponsors for CC-220

See all CC-220 clinical trials

US Patents for CC-220

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-220 ⤷  Sign Up Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies Celgene Corporation (Summit, NJ) ⤷  Sign Up
CC-220 ⤷  Sign Up Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione Celgene Corporation (Summit, NJ) ⤷  Sign Up
CC-220 ⤷  Sign Up Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast Celgene Corporation (Summit, NJ) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.